38 related articles for article (PubMed ID: 11822754)
1. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Fountzilas C; Javle M; Tan W; Ma Y; Fetterly G; Iyer R; Johnson C
Cancer; 2018 Oct; 124(19):3890-3899. PubMed ID: 30299542
[TBL] [Abstract][Full Text] [Related]
2. Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.
Yu J; Mu Q; Perazzolo S; Griffin JI; Zhu L; McConnachie LA; Shen DD; Ho RJ
Pharm Res; 2020 Sep; 37(10):197. PubMed ID: 32968837
[TBL] [Abstract][Full Text] [Related]
3. Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics.
Lecca P; Morpurgo D; Fantaccini G; Casagrande A; Priami C
BMC Syst Biol; 2012 May; 6():51. PubMed ID: 22640931
[TBL] [Abstract][Full Text] [Related]
4. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.
Anand S; Penrhyn-Lowe S; Venkitaraman AR
Cancer Cell; 2003 Jan; 3(1):51-62. PubMed ID: 12559175
[TBL] [Abstract][Full Text] [Related]
5. Prediction Model for Severe Thrombocytopenia Induced by Gemcitabine Plus Cisplatin Combination Therapy in Patients with Urothelial Cancer.
Matsumoto N; Mizuno T; Ando Y; Kato K; Nakanishi M; Nakai T; Lee JK; Kameya Y; Nakamura W; Takahara K; Shiroki R; Yamada S
Clin Drug Investig; 2024 May; 44(5):357-366. PubMed ID: 38684605
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria.
Peyclit L; Baron SA; Hadjadj L; Rolain JM
Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326755
[TBL] [Abstract][Full Text] [Related]
7. A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.
Liang Y; Zhang J; Tian B; Wu Z; Svirskis D; Han J
Int J Nanomedicine; 2020; 15():841-855. PubMed ID: 32103941
[TBL] [Abstract][Full Text] [Related]
8. Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.
Kozo D; Ross MW; Jarrah J; Barrett M; Harney RL; Courtney JB; Baburina I; Holleran JL; Beumer JH; Peters GJ; Honeywell RJ; Salamone SJ
Ther Drug Monit; 2017 Jun; 39(3):235-242. PubMed ID: 28490046
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Liang Y; Tian B; Zhang J; Li K; Wang L; Han J; Wu Z
Int J Nanomedicine; 2017; 12():1699-1715. PubMed ID: 28280336
[TBL] [Abstract][Full Text] [Related]
10. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
Shah DK; Balthasar JP
Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
[TBL] [Abstract][Full Text] [Related]
11. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
McKeage MJ; Jameson MB; Ramanathan RK; Rajendran J; Gu Y; Wilson WR; Melink TJ; Tchekmedyian NS
BMC Cancer; 2012 Oct; 12():496. PubMed ID: 23098625
[TBL] [Abstract][Full Text] [Related]
12. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
Gusella M; Pasini F; Bolzonella C; Meneghetti S; Barile C; Bononi A; Toso S; Menon D; Crepaldi G; Modena Y; Stievano L; Padrini R
Br J Clin Pharmacol; 2011 Mar; 71(3):437-44. PubMed ID: 21284703
[TBL] [Abstract][Full Text] [Related]
13. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
Srirangam A; Milani M; Mitra R; Guo Z; Rodriguez M; Kathuria H; Fukuda S; Rizzardi A; Schmechel S; Skalnik DG; Pelus LM; Potter DA
J Thorac Oncol; 2011 Apr; 6(4):661-70. PubMed ID: 21270666
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Li C; Sun Y; Pan Y; Wang Q; Yang S; Chen H
Lung; 2010 Oct; 188(5):359-64. PubMed ID: 20703493
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.
Stinchcombe TE; Socinski MA; Lee CB; Hayes DN; Moore DT; Goldberg RM; Dees EC
J Thorac Oncol; 2008 May; 3(5):521-6. PubMed ID: 18449006
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
[TBL] [Abstract][Full Text] [Related]
17. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Fogli S; Danesi R; De Braud F; De Pas T; Curigliano G; Giovannetti G; Del Tacca M
Ann Oncol; 2001 Nov; 12(11):1553-9. PubMed ID: 11822754
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
De Pas T; de Braud F; Danesi R; Sessa C; Catania C; Curigliano G; Fogli S; del Tacca M; Zampino G; Sbanotto A; Rocca A; Cinieri S; Marrocco E; Milani A; Goldhirsch A
Ann Oncol; 2000 Jul; 11(7):821-7. PubMed ID: 10997809
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
